Premium
Generation of the AD Informer Set: Chemical tools to facilitate Alzheimer’s disease drug discovery
Author(s) -
Potjewyd Frances M.,
AnnorGyamfi Joel K.,
Guduru Shiva K. R.,
Nwogbo Felix,
Rogers David A.,
Hopkins Meghan D.,
Conlon Ivie,
Wells Carrow,
Stashko Michael,
Hardy Brian P.,
Wang Xiaodong,
Frankowski Kevin,
Kireev Dmitri B.,
Pearce Kenneth H.,
Willson Tim,
Aubé Jeff,
Frye Stephen V.,
Richardson Timothy,
Young Jessica E.,
Axtman Alison D.
Publication year - 2021
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.051113
Subject(s) - disease , drug discovery , set (abstract data type) , computational biology , medicine , alzheimer's disease , clinical trial , neuroscience , bioinformatics , computer science , biology , pathology , programming language
Background Currently, treatments for Alzheimer’s disease (AD) predominantly include acetylcholinesterase inhibitors, which address the symptomatic effects of the disease. The discovery of disease modifying interventions in the development and progression of AD are critical as there are currently no drugs or biologics which can elicit disease modifying effects. Promisingly there is an increase in the number of novel therapeutic strategies targeting AD that have progressed to clinical trials, and interrogation of targets implicated in AD pathology remains an area of extensive research. Method To assist the discovery of novel strategies that slow or halt AD pathology we have generated the AD Informer Set, the first iteration of which contains more than 150 chemical tools. We will make solutions of the physical set as well as all associated data available to the scientific community in 2021. Further data is being collected on compound kinetic solubility, pharmacokinetic properties, potential off‐target liabilities, and AD‐specific readouts, including mitochondrial metabolism, oxidative stress and glycolysis, and effects on p‐Tau and Aβ expression levels. Result The AD Informer Set includes compounds for targets that have AD implicated biology, either well validated or recently suggested, and contains relevant information about the gene, compound structure and activity, and associated AD phenotypes. 1, 2Conclusion The AD Informer Set will be shared with the scientific community at large to qualify assays, interrogate target validity in AD models, and to provide positive controls to aid in the discovery of new chemical entities. References: (1) Hodes RJ, Buckholtz N. Accelerating Medicines Partnership: Alzheimer's Disease (AMP‐AD) Knowledge Portal Aids Alzheimer's Drug Discovery through Open Data Sharing. Expert Opin Ther Targets . 2016, 20, 389‐91. PMID: 26853544. (2) Mullard A. NIH launches open science Alzheimer initiative. Nat Rev Drug Discov . 2019, 18, 895. PMID: 31780852.